0000875320-26-000204
SEC filingVertex Pharmaceuticals shareholders at the May 13, 2026 Annual Meeting elected ten directors, ratified Ernst & Young LLP as auditors, approved the 2026 Stock and Option Plan, and advisory say-on-pay.
The Annual Meeting results reflect strong shareholder support for Vertex's Board of Directors, with all ten nominees elected despite varying opposition levels, the highest for Bruce Sachs at 209.7M against votes. The approval of the 2026 Stock and Option Plan under Item 5.02, which replaces the 2013 plan, passed with over 216M for votes, enabling continued equity-based compensation aligned with shareholder approval obtained at the meeting. Auditor ratification and advisory say-on-pay also garnered majority support, signaling confidence in financial oversight and executive pay practices. The passage of the shareholder proposal on written consent rights introduces potential governance flexibility.